A pilot study to test the feasibility, safety and efficacy of the addition of the BiTE antibody Blinatumomab to the Interfant-06 backbone in infants with MLL-rearranged acute lymphoblastic leukemia. A collaborative study of the Interfant network
Latest Information Update: 19 Sep 2024
At a glance
- Drugs Blinatumomab (Primary)
- Indications Precursor B-cell lymphoblastic leukaemia-lymphoma
- Focus Adverse reactions
- Acronyms Blinatumomab in infant ALL
- 19 Sep 2024 This trial has been completed in Belgium (Global end date: 2024-03-07) according to European Clinical Trials Database record.
- 27 Jun 2024 This trial has been completed in the Denmark, according to European Clinical Trials Database record.
- 19 Jun 2024 This trial has been completed in the Czech Republic, according to European Clinical Trials Database record.